BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a ...

Vertex Pharmaceuticals Incorporated VRTX has entered into an agreement to acquire ViaCyte, a private cellular therapy company, to accelerate the development of the VX-880 program in type I diabetes.

ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex’s fully differentiated, insulin-producing, stem cell derived islets ViaCyte to be acquired for ...

- Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data - - Phase 2 study of VX-864 continues to enroll and dose patients; ...

Vertex Pharmaceuticals (VRTX) is a biotechnology company that has multiple medicines approved by the U.S. Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF), in addition to ...

Vertex has stopped development of VX-961 after getting a look at phase 1 data. The NaV1.8 inhibitor failed to meet Vertex’s desired pharmacokinetic and tolerability profile, leading it to dump the ...